LY-411575: Potent γ-Secretase Inhibitor with IC50 0.078 nM for Alzheimer's and Cancer Research

Executive Summary: LY-411575 is a highly potent and selective γ-secretase inhibitor with an IC50 of 0.078 nM in membrane-based and 0.082 nM in cell-based assays, enabling direct suppression of amyloid beta (Aβ40, Aβ42) production and Notch signaling in preclinical models (APExBIO). The compound demonstrates in vivo efficacy by reducing brain and plasma Aβ levels in transgenic CRND8 mice at 1–10 mg/kg orally. LY-411575 inhibits Notch S3 cleavage (IC50 0.39 nM), impacting cancer processes such as leukemia and triple-negative breast cancer (TNBC) via Notch pathway modulation (Shen et al., 2024). As a research tool, it is supplied as a solid, with high solubility in DMSO (≥23.85 mg/mL) and ethanol (≥98.4 mg/mL, ultrasonic treatment), but insoluble in water. APExBIO provides LY-411575 (A4019) for advanced Alzheimer's and oncology workflows with validated protocols.

Biological Rationale

γ-Secretase is an intramembrane aspartyl protease complex responsible for cleaving type-I membrane proteins, including amyloid precursor protein (APP) and Notch receptors (APExBIO). Inhibition of γ-secretase blocks the formation of neurotoxic amyloid beta peptides (Aβ40, Aβ42), which are central to Alzheimer's disease pathology (internal link). The Notch signaling pathway, regulated by γ-secretase-mediated cleavage, controls cell fate, differentiation, and survival in various tissues. Aberrant Notch activation drives oncogenesis in several cancers, notably triple-negative breast cancer, by modulating cytokine secretion, tumor immune microenvironment, and metastasis (Shen et al., 2024). Thus, selective γ-secretase inhibition with LY-411575 enables dual-pathway interrogation for both neurodegenerative and oncological research.

Mechanism of Action of LY-411575

LY-411575 binds to the active site of presenilin, the catalytic subunit of γ-secretase (APExBIO). This interaction blocks the cleavage of APP, reducing Aβ40 and Aβ42 production. In parallel, LY-411575 inhibits Notch S3 cleavage (IC50 0.39 nM), preventing nuclear translocation of the Notch intracellular domain (NICD) and downstream transcriptional activation (Shen et al., 2024). The resulting downregulation of Notch signaling induces apoptosis in tumor cells and modulates immune cell recruitment within the tumor microenvironment (internal link). These effects have been validated in in vitro enzyme assays, cell-based models, and mouse studies.

Evidence & Benchmarks

• LY-411575 inhibits γ-secretase with an IC50 of 0.078 nM (membrane-based) and 0.082 nM (cell-based) (APExBIO, product page).
• Oral administration of LY-411575 (1–10 mg/kg) in CRND8 mice reduces brain and plasma Aβ levels, confirming in vivo efficacy (APExBIO).
• LY-411575 blocks Notch S3 cleavage with an IC50 of 0.39 nM, modulating Notch-dependent cytokine programs in cancer (Shen et al., 2024).
• Inhibition of Notch signaling by LY-411575 depletes tumor-associated macrophages (TAMs) and increases CD8+ cytotoxic T cell infiltration in TNBC models (Shen et al., 2024).
• Solubility benchmark: ≥23.85 mg/mL in DMSO, ≥98.4 mg/mL in ethanol (ultrasonic treatment); insoluble in water (APExBIO).
• Formulated for animal dosing in polyethylene glycol, propylene glycol, ethanol, and methylcellulose vehicles (APExBIO).

This article extends "LY-411575: Potent γ-Secretase Inhibitor with IC50 0.078 n..." by providing updated, cross-validated evidence on Notch pathway immune modulation in cancer models.

It clarifies the mechanistic insights presented in "LY-411575: Unraveling γ-Secretase Inhibition for Tumor Im..." by enumerating new in vivo immune microenvironment data not covered previously.

Applications, Limits & Misconceptions

Applications

• Alzheimer's disease research: Suppression of Aβ40/42 production in vitro and in vivo (APExBIO).
• Cancer research: Modulation of Notch signaling in leukemia, TNBC, and Kaposi's sarcoma (Shen et al., 2024).
• Experimental models: Used for mechanistic studies of intramembrane aspartyl protease inhibition.
• Immunology: Alters tumor immune microenvironment by reducing TAMs and promoting cytotoxic T cell responses.

Common Pitfalls or Misconceptions

• LY-411575 is not water-soluble; using aqueous vehicles reduces bioavailability and efficacy.
• Not suitable for long-term solution storage; degraded activity observed in DMSO or ethanol over time.
• Effects are not Notch-specific: γ-secretase inhibition also impacts APP and other substrates.
• In vivo effects in mice may not translate directly to human disease models without further validation.
• Does not abrogate all forms of tumor immune suppression—works mainly via TAM and T cell modulation (Shen et al., 2024).

Workflow Integration & Parameters

• Stock solutions: Prepare at 10 mM in DMSO; warm or sonicate to enhance dissolution.
• Working concentrations: Validate dose-response in the intended biological system; typical in vivo dosing 1–10 mg/kg orally in mice.
• Formulation: For animal studies, dissolve in vehicle of polyethylene glycol, propylene glycol, ethanol, and methylcellulose (APExBIO).
• Storage: Store solid at -20°C; avoid long-term storage of solutions.
• Recommended controls: Use selective Notch or APP pathway readouts to confirm pathway engagement.

Conclusion & Outlook

LY-411575, available from APExBIO as A4019, is a validated γ-secretase inhibitor with atomic-level selectivity and potency for both Alzheimer's and cancer research. It enables precise modulation of amyloid beta production and Notch signaling, supporting advanced mechanistic and translational workflows. Recent evidence highlights its role in reshaping the tumor immune microenvironment, especially in aggressive cancers like TNBC. Limitations include solubility constraints and the need for careful experimental validation across species. Continued investigation into γ-secretase biology and immune modulation is expected to further expand the utility of LY-411575 in preclinical research (Shen et al., 2024).